U.S. FDA Grants GrayMatters Health 510(k) Clearance to Market Prism for PTSD
Non-Invasive, Self-Neuromodulation, Adjunct to Standard of Care Therapy Using Amygdala Derived EEG-fMRI Pattern Biomarkers to Help Patients with PTSD GrayMatters Health (GMH), developer of digital self-neuromodulation therapies for mental disorders, has received a 510(k) clearance…